NCT00738530View on ClinicalTrials.gov

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

PHASE3CompletedINTERVENTIONAL
Enrollment

649

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Renal Cell Cancer
Interventions
DRUG

Bevacizumab [Avastin]

10 mg/kg IV every 2 weeks

DRUG

Interferon alfa 2a [Roferon]

9 MIU SC 3 times/week

DRUG

Placebo

IV every 2 weeks

Trial Locations (104)

407

Taichung

807

Kaohsiung City

1000

Brussels

1122

Budapest

1200

Brussels

1205

Geneva

2020

Antwerp

2031

Sydney

2139

Sydney

2606

Canberra

2610

Wilrijk

3010

Bern

3128

Melbourne

3199

Frankston

4006

Brisbane

4031

Basel

4068

Stavanger

5011

Adelaide

5037

Kurralta Park

5041

Adelaide

6009

Perth

6026

Ålesund

7000

Trondheim

9700

Szombathely

10126

Torino

13273

Marseille

14076

Caen

18014

Granada

20089

Rozzano

20133

Milan

20162

Milan

20520

Turku

28040

Madrid

28041

Madrid

29010

Málaga

30449

Hanover

31052

Toulouse

33075

Bordeaux

33520

Tampere

35043

Marburg

36002

Pontevedra

38043

Grenoble

39008

Santander

41100

Modena

44805

Saint-Herblain

46009

Valencia

49933

Angers

50009

Zaragoza

52621

Ramat Gan

57100

Livorno

58100

Holon

59020

Lille

63011

Clermont-Ferrand

64283

Darmstadt

67091

Strasbourg

68167

Mannheim

69373

Lyon

70300

Ẕerifin

76100

Rehovot

80131

Napoli

81377

München

86021

Poitiers

87042

Limoges

92151

Suresnes

94805

Villejuif

105229

Moscow

107005

Moscow

115478

Moscow

119074

Singapore

125284

Moscow

129128

Moscow

169610

Singapore

197758

Saint Petersburg

249020

Obninsk

6423906

Tel Aviv

430 12

Chomutov

370 87

České Budějovice

500 05

Hradec Králové

305 99

Pilsen

06189

Nice

Unknown

Berlin

Hamburg

Planegg

Moscow

Saint Petersburg

Chang Gung

06122

Perugia

00144

Roma

1081 HV

Amsterdam

6525 GA

Nijmegen

0310

Oslo

85-796

Bydgoszcz

31-826

Krakow

94-306

Lodz

10-228

Olsztyn

33-100

Tarnów

00-909

Warsaw

08035

Barcelona

08036

Barcelona

08041

Barcelona

00112

Taipei

NW3 2QG

London

SE1 9RT

London

M2O 4BX

Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00738530 - A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy | Biotech Hunter | Biotech Hunter